Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Powel Brown
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
- Chaim Sheba Medical Center
Tel Litwinsky, Israel
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Nyp/columbia University Medical Center/herbert Irving Comprehensive Cancer Center
New York, New York, United States
- Nyp/weill Cornell Medical Center
New York, New York, United States
- M D Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Mar 2019
- Primary completion
- 22 Oct 2021
- Completion
- 22 Oct 2021
- Last update posted
- 14 Jun 2022
- Registered enrollment
- 2
- Registry id
- NCT03382574
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.